Many patients benefit from personalized medicines. This article from Cambridge University Press (December 15, 2023), discusses the new European Medicines Agency (EMA) guideline on antidepressants, highlighting its significance for researchers and drug developers.
This guideline is vital in addressing the high prevalence and burden of depressive disorders, especially in light of the COVID-19 pandemic. It emphasizes the need for more effective and personalized medicinal products to treat major depressive disorders (MDD), as current treatments often fail to achieve full remission in many patients.
The guideline covers various aspects of clinical trials for antidepressants, including design, methodology, and considerations for specific patient populations. This revision aims to facilitate the development and approval of new, more effective treatment options, reflecting the latest advances in MDD research and the emergence of new therapies.
For detailed information, you can read the full article here.